Senescent vascular smooth muscle cells take center stage in diabetic atherosclerosis

Diabetic atherosclerosis, the most severe macrovascular complication of diabetes mellitus and a major contributor to global morbidity and mortality, has a hidden driver that researchers struggle to see clearly: senescent vascular smooth muscle cells. A review published in Frontiers in Endocrinology argues that these aged, dysfunctional cells are increasingly recognized as a central mechanism behind plaque formation, progression and instability under diabetic conditions, yet reliably identifying them remains a stubborn methodological challenge.

The problem is threefold. Available biomarkers lack specificity, transcriptomic signatures vary considerably across studies, and no consensus has emerged on how senescence should be verified methodologically. Without a standardized way to confirm that a vascular smooth muscle cell has truly entered a senescent state, findings from different laboratories can be difficult to compare, and potential therapeutic targets may be mislabeled or overlooked.

To address this, the authors consolidate current knowledge on identifying senescent vascular smooth muscle cells in diabetic atherosclerosis, starting with the pathobiological routes through which hyperglycemia drives these cells into senescence: oxidative stress, DNA damage, mitochondrial dysfunction and metabolic reprogramming. Together these pathways illustrate why diabetic vessels provide fertile ground for cellular aging processes that accelerate arterial disease.

A substantial portion of the review is devoted to a multidimensional classification of senescence-associated biomarkers, spanning cell cycle regulators, senescence-associated β-galactosidase, telomere-related markers, the senescence-associated secretory phenotype, calcification markers and emerging non-coding RNA signatures. For each category, the authors assess both applicability and shortcomings, underscoring that no single marker is sufficient on its own.

Beyond individual markers, the review integrates transcriptomic signatures derived from single-cell RNA sequencing, spatial transcriptomics and flow cytometry to map the heterogeneity of senescent vascular smooth muscle cell subpopulations and their functional roles within atherosclerotic plaques. Rather than treating plaques as uniform structures, this approach reveals that senescent cells occupy distinct niches and may contribute differently to plaque vulnerability depending on their location and molecular profile.

The methodological appraisal is perhaps the review’s most consequential contribution. The authors compare in vitro high-glucose models, in vivo diabetic animal models and clinical specimens, tracing the sources of inter-study inconsistency. Spatial heterogeneity within plaques, cross-sectional study designs and the absence of standardized protocols all emerge as key culprits. A marker that appears robust in cultured cells exposed to high glucose may behave quite differently in a diabetic mouse model or in human plaque tissue obtained during surgery.

In response, the review outlines a stepwise identification pipeline extending from molecular markers to functional validation and multi-omics integration. The proposed framework moves beyond reliance on any single indicator, requiring convergent evidence before a cell can be confidently labeled senescent. The authors also look ahead to future prospects, including senolytic therapies designed to eliminate senescent cells and targeted delivery systems aimed at reaching them selectively within vascular lesions. These therapeutic concepts depend directly on accurate identification, and the authors present them as directions for future work rather than established clinical benefits.

By providing this methodological reference, the authors hope to support both basic research and clinical translation and to push the field toward more precise, standardized identification of senescent vascular smooth muscle cells.

Subject of Research: Identification of senescent vascular smooth muscle cells in diabetic atherosclerosis through biomarkers, transcriptomic signatures and methodological validation

Article Title: Recognizing senescent vascular smooth muscle cells in diabetic atherosclerosis: biomarkers, transcriptomic signatures, and methodological validity

Article References: Yang, X., & Zhao, D. (2026). Recognizing senescent vascular smooth muscle cells in diabetic atherosclerosis: biomarkers, transcriptomic signatures, and methodological validity. Frontiers in Endocrinology, 17, Article 1997338. https://doi.org/10.3389/fendo.2026.1997338

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1997338

Keywords: diabetic atherosclerosis, vascular smooth muscle cells, cellular senescence, biomarkers, single-cell RNA sequencing, senescence-associated secretory phenotype, SA-β-gal, hyperglycemia, senolytic therapies, spatial transcriptomics, Recognizing, senescent